ArticleMedical principles and practice : international journal of the Kuwait University, Health Science Centre2026
Hepatic Immunomodulatory Effect of Belatacept on the TNF-α/IL-6 Pro-Inflammatory Axis and Its Impact on Regulation of MiRNA-146a in Hepatic Injury.
Article in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcute liver injury is associated with a systemic cytokine release that determines the clinical prognosis. Although there are many hepatoprotective drugs, their unique immunomodulatory profiles are still unclear. This study evaluates the therapeutic potential of Belatacept versus Prednisolone on miRNA-146a expression and the pro-inflammatory cytokine cascade in a rat model of Concanavalin A-induced hepatic damage. MATERIALS AND
methodsThe animal model of liver injury was induced in adult male Wistar rats by dividing them in 4 groups: normal controls, liver injury, prednisolone, and belatacept-treated groups. The serum levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were used to determine the systemic inflammation and were measured by enzyme-linked immunosorbent assay. RT-qPCR was used to quantify the expression of hepatic miRNA-146a. Statistical significance was established by using one-way ANOVA (p < 0.05).
resultsTNF-α and IL-6 levels in serum increased significantly, in response to inducing hepatic damage (p < 0.05). Alongside this, a notable dysregulation of miRNA-146a was detected. Belatacept treatment successfully inhibited the cytokine systemic response, bringing IL-6 down to levels that were statistically more significant than those attained by prednisolone (p < 0.01), while TNF-α reduction was comparable in both groups (p > 0.05). Additionally, Belatacept treatment effectively upregulates miRNA-146a levels, achieving a restoration profile which was statistically more significant than prednisolone (p < 0.01).
conclusionThese findings show that belatacept has stronger immunomodulatory action when compared with standard therapy. Belatacept is a promising new treatment option for liver-driven systemic inflammation which acts by inhibiting the TNF-α/IL-6 axis and modulating miRNA-146a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.